阿帕他胺新型内分泌治疗结合手术实现局限性高危前列腺癌病理完全缓解1例报道

doi:10.19558/j.cnki.10-1020/r.2022.02.011

摘要
图/表
参考文献
相关文章 (14)

[1] SIEGEL R L, MILLER K D, JEMAL A.Cancer statistics,2018[J]. CA Cancer J Clin,2018,68(1):7-30.
[2] 顾秀瑛,郑荣寿,张思维,等.2000Mille年中国肿瘤登记地区前列腺癌发病趋势及年龄变化分析[J].中华预防医学杂志,2018,52(6):586-592.
[3] CORNFORD P, VAN DEN BERGH R, BRIERS E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II-2020 update: treatment of relapsing and metastatic prostate cancer[J]. Eur Urol,2021,79(2):263-282.
[4] DEVOS G, DEVLIES W, DE M G, et al.Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer[J]. Nat Rev Urol,2021,18(12):739-762.
[5] ASLIM E J, YANG X, NGO N T, et al.1037-Neoadjuvant apalutamide(arn-509)and radical prostatectomy in treatment of intermediate to high risk prostate cancer(NEAR)-initial results of a phase II trial[J]. Eur Urol Suppl,2019,18(1):e1394.
[6] COOPERBERG M R, BROERING J M, CARROLL P R.Time trends and local variation in primary treatment of localized prostate cancer[J]. J Clin Oncol,2010,28(7):1117-1123.
[7] CHI K N, PROTHEROE A, RODRÍGUEZ-ANTOLÍN A, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE):an international, randomised phase 3 trial[J]. Lancet Oncol,2018,19(2):194-206.
[8] YOSSEPOWITCH O, EGGENER S E, SERIO A M, et al.Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy[J]. Eur Urol,2008,53(5):950-959.
[9] GIANNI L, PIENKOWSKI T, IM Y H, et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere):a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol,2012,13(1):25-32.
[10] TAPLIN M E, MONTGOMERY B, LOGOTHETIS C J, et al.Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study[J]. J Clin Oncol,2014,32(33):3705-3715.
[11] YE D, ZHANG W, MA L, et al.Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China[J]. Chin J Cancer Res,2019,31(3):511-520.